|本期目录/Table of Contents|

[1]杜春蕾,郭 牧,张云强,等.尼非卡兰和胺碘酮治疗急性心肌梗死新发房颤有效性和安全性对比研究[J].天津医科大学学报,2019,25(05):471-474+480.
 DU Chun-lei,GUO Mu,ZHANG Yun-qiang,et al.Comparison of nifekalant and amiodarone in the treatment of new-onset atrial fibrillation in acute myocardial infarction patients[J].Journal of Tianjin Medical University,2019,25(05):471-474+480.
点击复制

尼非卡兰和胺碘酮治疗急性心肌梗死新发房颤有效性和安全性对比研究(PDF)
分享到:

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:
25
期数:
2019年05期
页码:
471-474+480
栏目:
临床医学
出版日期:
2019-09-20

文章信息/Info

Title:
Comparison of nifekalant and amiodarone in the treatment of new-onset atrial fibrillation in acute myocardial infarction patients
文章编号:
1006-8147(2019)05-0471-04
作者:
杜春蕾12郭 牧2张云强2梁海青2田树光2王 钊2宋 昱2
(1.天津医科大学研究生院,天津 300070;2. 泰达国际心血管病医院CCU,天津 300457)
Author(s):
DU Chun-lei12 GUO Mu2 ZHANG Yun-qiang2 LIANG Hai-qing2 TIAN Shu-guang2 WANG Zhao2 SONG Yu2
(1.Gradute School, Tianjin Medical University, Tianjin 300070, China; 2.CCU, TEDA International Cardiovascular Hospital,Tianjin 300457, China)
关键词:
急性心肌梗死心房颤动尼非卡兰胺碘酮
Keywords:
acute myocardial infarction atrial fibrillation nifekalantamiodarone
分类号:
R542.2+2
DOI:
-
文献标志码:
A
摘要:
目的:探讨尼非卡兰和胺碘酮治疗急性心肌梗死新发房颤的有效性和安全性。方法:纳入泰达国际心血管病医院重症监护室2017年1月- 2018年5月收治的急性心肌梗死合并新发房颤的患者共106例,按计算机产生的随机序号分为尼非卡兰组52例和胺碘酮组54例,分别予尼非卡兰(注射用盐酸尼非卡兰,50 mg):负荷剂量:0.3 mg/kg输注5 min,维持剂量:0.4 mg/kg/h;胺碘酮(盐酸胺碘酮注射液,可达龙,3 mL:0.15 g):负荷剂量:15 mg/min输注10 min,维持剂量:1 mg/min治疗,观察2组患者24 h房颤转复率及控制率,治疗前后血压、心率、左心室射血分数、不良反应等。结果:尼非卡兰组和胺碘酮组的房颤转复率分别为50(96%)、42(78%),具有统计学差异(P=0.001)。尼非卡兰组转复时间较短(2.7±1.3,P=0.02),24 h房颤发作控制率未见明显统计学差异(P=0.16),但尼非卡兰组相对比例较高(77%)。尼非卡兰组对收缩压(P=0.24)、舒张压(P=0.32)、心率(P=0.23)未见明显影响,可升高LVEF(P=0.001)、延长QTc(P=0.001)。不良反应方面,尼非卡兰组发生率低,仅1例尖端扭转室速,停药后恢复,总体不良反应发生率与胺碘酮组无明显统计学差异(P=0.27)。结论:尼非卡兰对急性心肌梗死新发房颤的治疗效果显著,对血压心率影响小,不良反应发生率低。
Abstract:
Objective: To compare nifekalant and amiodarone in the treatment of new-onset atrial fibrillation in acute myocardial infarction patients. Methods:Patients admitted to TEDA International Cardiovascular Hospital from January 2017 to May 2018 with acute myocardial infarction and new-onset atrial fibrillation were randomized into 52 patients in the nifekalant group and 54 patients in amiodarone group according to random numbers produced by computer. Those two groups were treated with nifekalant(loading dose: 0.3 mg/kg infusion for 5 minutes; maintenance dose: 0.4 mg/kg/h) and amiodarone(loading dose: 15 mg/min infusion for 10 minutes; maintenance dose: after 1 mg/min treatment).The 24-hour recovery rate and control rate of atrial fibrillation in the two groups were observed, and blood pressure, heart rate, left ventricular ejection fraction, and adverse reactions before and after treatment were measured. Results: A total of 106 patients with acute myocardial infarction complicated with new-onset atrial fibrillation were enrolled in this study. The rates of atrial fibrillation reversal in the nifekalant and amiodarone groups were 50(96%)and 42(78%)respectively, with statistical significance (P=0.001). The time of conversion was shorter in the nifekalant group(2.7±1.3, P=0.02), and the control rate of atrial fibrillation at 24 hours was not significantly different(P=0.16), but the relative proportion was higher in the nifekalant group(77%). The nifekalant group had no significant effect on systolic blood pressure (P=0.24), diastolic blood pressure (P=0.32), and heart rate (P=0.23), and increased LVEF(P=0.001)and prolonged QTc(P=0.001). Adverse reactions caused by nifekalant was low, and there was no significant difference between those two groups (P=0.27). Conclusion:Nifekalant has a significant effect on the treatment of new-onset atrial fibrillation in patients with acute myocardial infarction. It has little effect on the blood pressure and heart rate and the incidence of adverse reactions is low.

参考文献/References:

[1] Rene A G, Généreux P, Ezekowitz M, et al. Impact of atrial fibrillation in patients with ST-elevation myocardial infarction treated with percutaneous coronary intervention(from the HORIZONS-AMI [Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction] trial)[J]. Am J Cardiol, 2014,113(2):236
[2] Chen L Y, Benditt D G, Alonso A. Atrial fibrillation and its association with sudden cardiac death[J]. Circ J, 2014,78(11): 2588
[3] Rahman F, Kwan G F, Benjamin E J. Global epidemiology of atrial fibrillation[J]. Nat Rev Cardiol, 2016,13(8): 501
[4] Stamboul K, Zeller M, Fauchier L, et al. Incidence and prognostic significance of silent atrial fibrillation in acute myocardial infarction[J]. Int J Cardiol, 2014,174(3): 611
[5] Zhang E Y, Cui L, Li Z Y, et al. High Killips Class as a Predictor of New-onset Atrial Fibrillation Following Acute Myocardial Infarction: Systematic Review and Meta-analysis[J]. Chin Med J (Engl),2015,128(14):1964
[6] Hu Y F, Chen Y J, Lin Y J, et al. Inflammation and the pathogenesis of atrial fibrillation[J]. Nat Rev Cardiol, 2015,12(4):230
[7] Igarashi T, Niwano S, Fukaya H, et al. Discrimination of Paroxysmal and Persistent Atrial Fibrillation in Patients With New-Onset Atrial Fibrillation[J]. Int Heart J, 2016, 57(5): 573
[8] Kawabata M, Sasaki T, Maeda S, et al. Rivaroxaban for Periprocedural anticoagulation therapy in Japanese patients undergoing catheter ablation of paroxysmal non-valvular atrial fibrillation[J]. Int Heart J,2016,57(6):712
[9] Andersson T, Magnuson A, Bryngelsson I L, et al. All-cause mortality in 272,186 patients hospitalized with incident atrial fibrillation 1995-2008: a Swedish nationwide long-term case-control study[J]. Eur Heart J, 2013,34(14):1061
[10] González-Pacheco H, Eid-Lidt G, Altamirano-Castillo A, et al. Prevalence and prognostic implications of different types of atrial fibrillation in patients admitted to a coronary care unit[J]. Int J Cardiol, 2014,172(2):e379
[11] 张明亮, 张焕轶, 刘燕, 等. P波离散度与TIMI危险评分对STEMI患者新发房颤的预测价值[J]. 中华临床医师杂志(电子版),2016,10(01):1
[12] Parashar S, Kella D, Reid K J, et al. New-onset atrial fibrillation after acute myocardial infarction and its relation to admission biomarkers(from the TRIUMPH registry)[J]. Am J Cardiol,2013,112(9):1390
[13] Minamisawa M, Motoki H, Izawa A, et al. Comparison of Inflammatory Biomarkers in Outpatients With Prior Myocardial Infarction[J]. Int Heart J, 2016, 57(1):11
[14] Lundberg A M, Ketelhuth D F, Johansson M E, et al. Toll-like receptor 3 and 4 signalling through the TRIF and TRAM adaptors in haematopoietic cells promotes atherosclerosis[J]. Cardiovasc Res,2013, 99(2):364
[15] Hovland A, Jonasson L, Garred P, et al. The complement system and toll-like receptors as integrated players in the pathophysiology of atherosclerosis[J]. Atherosclerosis, 2015,241(2):480
[16] Ogawa K, Hirooka Y, Kishi T, et al. Partially silencing brain toll-like receptor 4 prevents in part left ventricular remodeling with sympathoinhibition in rats with myocardial infarction-induced heart failure[J]. PLoS One, 2013,8(7):e69053
[17] Xu Y, Sharma D, Du F, et al. The role of Toll-like receptor 2 and hypoxia-induced transcription factor-1α in the atrial structural remodeling of non-valvular atrial fibrillation[J]. Int J Cardiol,2013, 168(3):2940
[18] Zhang P, Shao L, Ma J. Toll-Like Receptors 2 and 4 Predict New-Onset Atrial Fibrillation in Acute Myocardial Infarction Patients[J]. Int Heart J, 2018,59(1):64
[19] Dai Y, Yang J, Gao Z, et al. Atrial fibrillation in patients hospitalized with acute myocardial infarction: analysis of the china acute myocardial infarction (CAMI) registry[J]. BMC Cardiovasc Disord,2017,17(1):2
[20] Nakaya H, Tohse N, Takeda Y, et al. Effects of MS-551, a new class III antiarrhythmic drug, on action potential and membrane currents in rabbit ventricular myocytes[J]. Br J Pharmacol,1993,109(1):157
[21] Hohnloser S H, van de Loo A, Baedeker F. Efficacy and proarrhythmic hazards of pharmacologic cardioversion of at rial fibrillation: prospective comparison of sotalol versus quinidine[J]. J Am Coll Cardiol, 1995,26(4):852
[22] Wang J, Bourne G W, Wang Z, et al. Comparative mechanisms of antiarrhythmic drug action in experimental atrial fibrillation. Importance of use-dependent effects on refractoriness[J]. Circulation, 1993, 88(3):1030
[23] Morillo C A, Klein G J, Jones D L, et al. Chronic rapid atrial pacing. Structural, functional, and electrophysiological characteristics of a new model of sustained atrial fibrillation[J]. Circulation,1995,91(5):1588
[24] Wijffels M C, Kirchhof C J, Dorland R, et al. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats[J]. Circulation, 1995, 92(7):1954

相似文献/References:

[1]段雯婷,马向红,李广平.QRS碎裂波对行介入治疗的急性心肌梗死患者不良心血管事件的影响[J].天津医科大学学报,2014,20(02):111.
 DUAN Wen-ting,MA Xiang-hong,LI Guang-ping.Effect of fQRS on main adverse cardiac events in patients with acute myocardial infarction undergoing coronary intervention[J].Journal of Tianjin Medical University,2014,20(05):111.
[2]马长辉,杨万松.血清丙氨酸转氨酶与ST段抬高型心肌梗死的相关性研究[J].天津医科大学学报,2014,20(02):116.
 MA Chang-hui,YANG Wan-song.Clinical study of serum alanine aminotransferase in patients with acute ST-segment elevation myocardial infarction[J].Journal of Tianjin Medical University,2014,20(05):116.
[3]杨寿娟,刘 寅,赵 茹.血小板减少症伴肺栓塞患者合并急性心肌梗死1例报道[J].天津医科大学学报,2014,20(06):496.
[4]张 坤,李广平,上官文锋.急诊PCI术对心肌梗死患者QTc、Tp-Te、Tp-Tec间期的影响[J].天津医科大学学报,2015,21(03):48.
 ZHANG Kun,LI Guang-ping,SHANGGUAN Wen-feng.Effects of primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction at QTc , Tp-Te and Tp-Tec interval[J].Journal of Tianjin Medical University,2015,21(05):48.
[5]王爱芬,崔利军,马向红.非瓣膜性心房颤动左心房/左心耳血栓形成的相关因素分析[J].天津医科大学学报,2015,21(02):130.
 WANG Ai-fen,CUI Li-jun,MA Xiang-hong.Related factors of left atrial or left atrial appendage thrombus formation in patients with non-valvular atrial fibrillation[J].Journal of Tianjin Medical University,2015,21(05):130.
[6]陈延勋,李广平. 非瓣膜性心房颤动患者尿酸与CHADS2、CHA2DS2-VASc评分的关系[J].天津医科大学学报,2015,21(03):185.
 CHEN Yan-xun,LI Guang-ping. Relationship between uric acid and CHADS2/CHA2DS2-VASc Score in patients with nonvalvular atrial fibrillation[J].Journal of Tianjin Medical University,2015,21(05):185.
[7]崔占前,徐延敏.脂蛋白相关性磷脂酶A2及高敏C反应蛋白与左心房内径的关系[J].天津医科大学学报,2015,21(03):196.
 CUI Zhan-qian,XU Yan-min.Relationship between plasma lipoprotein-associated phospholipase A2, high sensitivity C reactive protein and left atrial diameter[J].Journal of Tianjin Medical University,2015,21(05):196.
[8]张 坤,李广平,上官文锋.急诊PCI术对心肌梗死患者QTc、Tp-Te、Tp-Tec间期的影响[J].天津医科大学学报,2015,21(01):48.
 ZHANG Kun,LI Guang-ping,SHANGGUAN Wen-feng.Effects of primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction at QTc , Tp-Te and Tp-Tec interval[J].Journal of Tianjin Medical University,2015,21(05):48.
[9]付伟伟,李国东,王 喆.HDL-C与非瓣膜性心房颤动左心房/左心耳血栓形成的关系[J].天津医科大学学报,2015,21(06):498.
 FU Wei-wei,LI Guo-dong,WANG Zhe.Relationship between high-density lipoprotein cholesterol and left atrial / left atrial appendage thrombus in non-valvular atrial fibrillation patients[J].Journal of Tianjin Medical University,2015,21(05):498.
[10]张彦月,林文华.vWF及血浆D-二聚体水平对非瓣膜性心房颤动患者血栓形成的诊断及临床预后价值[J].天津医科大学学报,2016,22(02):101.
 ZHANG Yan-yue,LIN Wen-hua.Value of vWF and?D-dimer for thrombosis and prognosis in patients with non-valvular atrial fibrillation[J].Journal of Tianjin Medical University,2016,22(05):101.

备注/Memo

备注/Memo:
作者简介 杜春蕾(1990-),女,医师,硕士,研究方向:心血管病内科;通信作者:宋昱,E-mail:dr.songyu@163.com。
更新日期/Last Update: 2019-10-11